Autologous Immune Enhancement Therapy (AIET) for Cancer Patients
NCT ID: NCT05520372
Last Updated: 2022-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2016-01-01
2021-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT04162158
Immune Cell Therapy for Advanced Solid Tumors
NCT07260058
Infections Associated With the Use of Alemtuzumab
NCT01315457
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
NCT03535246
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
NCT05132855
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
autologous immune enhancement therapy (AIET) for treating cancer
A total of 60 cancer patients received one to seven sittings of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) infusions.
Autologous immune enhancement therapy (AIET) for cancer patients
Autologous NK cell and CD8 T cell therapy for cancer patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous immune enhancement therapy (AIET) for cancer patients
Autologous NK cell and CD8 T cell therapy for cancer patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients have been diagnosed with cancer.
* Patients signed the written informed consent form.
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vinmec Research Institute of Stem Cell and Gene Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liem Nguyen Thanh, PhD
Role: PRINCIPAL_INVESTIGATOR
Vinmec Research Institute of Stem Cell and Gene Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AIET_2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.